Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
GP1-H82E3 | Human | Biotinylated Human Glypican 1 Protein, His,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
GP1-H52H8 | Human | Human Glypican 1 / GPC1 (S486A, S488A, S490A) Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
|
GP1-M52H7 | Mouse | Mouse Glypican 1 / GPC1 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
GP1-H52H9 | Human | Human Glypican 1 / GPC1 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
GP1-H5254 | Human | Human Glypican 1 / GPC1 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Human FGF basic, premium grade (Cat. No. BFF-H4117) at 1 μg/mL (100 μL/well) can bind Mouse Glypican 1, His Tag (Cat. No. GP1-M52H7) with a linear range of 5-78 ng/mL (QC tested).
The purity of Biotinylated Human Glypican 1 Protein, His,Avitag (Cat. No. GP1-H82E3) is more than 90% and the molecular weight of this protein is around 55-75 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Miltuximab | MIL-38/Gallium67 | Phase 1 Clinical | Glytherix | Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms | Details |
This web search service is supported by Google Inc.